Does someone in your family have type 1 diabetes? If you answer "yes" to this question, you could get diabetes. Join the Diabetes Prevention Trial--Type 1 and help find out if this chronic disease can be prevented.
What Is the Diabetes Prevention Trial--Type 1?
The Diabetes Prevention Trial--Type 1 (DPT-1) is a nationwide study to see if we can prevent or delay type 1 diabetes, also known as insulin-dependent diabetes. Nine medical centers and more than 350 clinics in the United States and Canada are taking part in the study.
Diabetes has a genetic link; close relatives of people with the disease have an increased chance of developing it. These are the individuals being recruited for the DPT-1. All family members, including children, are eligible for a free test to determine their risk of getting diabetes.
What Is Type 1 Diabetes?
Type 1 diabetes is a life-long disorder that can occur in children or adults. It occurs when the body attacks and destroys the insulin-producing cells in the pancreas. Destruction of the cells is gradual and most symptoms of diabetes do not begin until almost all insulin-producing cells are destroyed. Most people do not realize they are developing diabetes until the damage is complete.
Who Should Be Tested?
You should be tested if you are:
- Age 3 to 45 and have a brother or sister, child, or parent with type 1 diabetes.
- Age 3 to 20 and have a cousin, uncle or aunt, nephew or niece, grandparent, or half-sibling with type 1 diabetes.
Your relative probably has type 1 diabetes if he or she:
- Developed diabetes before age 40 and
- Needs to take insulin injections.
If you meet these criteria, you can receive a free test to see whether your blood contains islet cell antibodies (ICA), the antibodies that destroy the insulin-producing cells. If the test shows that you have ICAs in your blood, you may be eligible to take part in the DPT-1.
How Will the DPT-1 Try to Prevent Type 1 Diabetes?
Animal research and small studies in people have indicated that type 1 diabetes can be delayed in those at high risk for the disease by regular, small doses of insulin. The DPT-1 is a large-scale study testing whether type 1 diabetes can be prevented or delayed in humans with insulin injections or insulin capsules. Participants will be enrolled in one of two studies based on their degree of risk for developing diabetes over the next five years:
Insulin Injection Trial: Individuals with a greater than 50 percent chance of getting diabetes will inject low doses of insulin twice a day. Once a year, they will go to a DPT-1 center to be admitted to a hospital for four days of insulin therapy.
Oral Insulin Trial: Individuals with a 25 percent to 50 percent chance of developing diabetes will take insulin orally in the form of a capsule. (For those who cannot swallow capsules, the crystals can be dissolved in juice.)
In each study, half of the participants will be randomly assigned to an insulin treatment group and half will be placed in a control group in which no insulin is given.
Why Should You Take Part in DPT-1?
If you are eligible to participate in the DPT-1, you are already at risk for developing diabetes. By taking part in the study, you may be able to prevent or delay the onset of the disease.
You will be closely monitored for signs of diabetes. If you develop diabetes, you will benefit from early detection and be able to begin immediate treatment, which may reduce your chances of developing serious complications later.
You will be part of an important effort to determine whether we can prevent or delay type 1 diabetes. This information could help other people, especially those in your own family.
How to Get Tested:
To get a free blood test or for more information about the DPT-1, call one of the nine centers listed below or dial (800) HALT-DM1 ([800] 425-8361) to receive an inquiry packet and information on where to schedule a blood test close to home.
You will be notified of test results. All information will be kept confidential.
DPT-1 Clinical Centers
There are more than 350 screening centers in the United States and Canada that are linked with the following clinical centers.
California
Childrens Hospital of Los Angeles
Box 61/ 4650 Sunset Boulevard
Los Angeles, CA 90027
Phone: (888) 835-3761
Fax: (323) 953-1349
Email: jvalenzuela@chla.usc.edu
University of Southern California
Los Angeles County Medical Center
Endocrine & Diabetes Service, Rm. 19629B
Los Angeles, CA 90033
Phone: (323) 226-7626
Fax: (323) 226-5709
Email: azeidler@hsc.usc.edu
Stanford University
S-302 Medical Center
Stanford, CA 94305-5119
Phone: (650) 725-0497
Fax: (650) 725-8375
Email: darrell@forsythe.stanford.edu
Colorado
Barbara Davis Center for Childhood Diabetes
Box B140/ 4200 East 9th Avenue
University of Colorado
Denver, CO 80262
Phone: (800) 572-3992
Fax: (303) 315-4124
Email: sherrie.harris@uchsc.edu
Florida
University of Florida
Box 100275
Gainesville, FL 32610-0275
Phone: (800) 749-7424, Ext. 2-7836, or (800) 552-0219
Fax: (352) 392-3053
Email: Dennis.pathology@mail.health.ufl.edu
University of Miami
P. O. Box 016960 (D-110)
Miami, FL 33101
Phone: (305) 243-DPT-1 (305-243-3781)
Fax: (305) 243-3313
Email: dmatheso@med.miami.edu
Massachusetts
Joslin Diabetes Center/Children's Hospital /Beth Israel Hospital
1 Joslin Place
Boston, MA 02215
Phone: (800) 2-HALT-DM ([800] 242-5836)
Fax: (617) 732-2432
Email: dconboy@joslin.harvard.edu
Minnesota
University of Minnesota
424 Harvard Street SE, Box 101
Masonic Bldg. Room 203
Minneapolis, MN 55455
Phone: (800) 688-5252, Ext. 58944
Fax: (612) 626-3133
Email: schmi094@maroon.tc.umn.edu
Washington
Virginia Mason Research Center
1201 9th Avenue
Seattle, WA 98101
Phone: (206) 515-5233
Fax: (206) 515-5239
Email: marli@vmresearch.org
Sponsored by: National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, American Diabetes Association, Juvenile Diabetes Foundation International, and National Center for Research Resources.
Additional promotional support and supplies provided by: Eli Lilly and Co., Becton-Dickinson & Co., Abbott Laboratories, Medisense Products, Bayer Corp., Bristol-Myer Squibb Co., Lifescan Inc., MiniMed Inc., Roche Diagnostics
For more information, please visit the National Institute of Diabetes and Digestive and Kidney Diseases' Web site, http://www.niddk.nih.gov.
The National Institute of Diabetes and Digestive and Kidney Diseases is a component of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services.
|
